Zeposia (ozanimod) is an oral sphingosine-1 phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Ayvakit (Avapritinib) for Gastrointestinal Stromal Tumor
Ayvakit (avapritinib) is an oral potent and selective inhibitor of activated KIT and PDGFRA mutant kinases, particularly activation loop mutations and highly resistant PDGFRA D842V mutation. It is indicated for the treatment of adults with unresectable or metastatic gastrointestinal s…
Vazegepant for Acute Treatment of Migraine
Vazegepant is an intranasal novel small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”) drug proposed for the acute treatment of migraine headache. CGRP is involved in vasodilation and sensory transmission and is a validated target for the treatment of migraine headache.
Nerivio Migra for Acute Treatment of Migraine
Nerivio Migra provides neuromodulation therapy through a noninvasive, wearable device. It is indicated for the acute treatment of migraine headache in adults who do not have chronic migraine. The Nerivio Migra system consists of a pair of electrodes mounted on an armband with a power source. The wireless device is self-applied to the upper arm and delivers transcutaneous elec…
Risdiplam for Spinal Muscular Atrophy
Risdiplam (formerly RG7916) is an investigational, oral small molecule SMN2-splicing modifier designed to help the survival motor neuron 2 (SMN2) gene produce more SMN protein. It is in development for the treatment of spinal muscular atrophy (SMA).
Nerivio Migra for Acute Treatment of Migraine
Nerivio Migra provides neuromodulation therapy through a noninvasive, wearable device. It is indicated for the acute treatment of migraine headache in adults who do not have chronic migraine. The Nerivio Migra system consists of a pair of electrodes mounted on an armband with a power source. The wireless device is self-applied to the upper arm and delivers transcutaneous elec…
WavelinQ (formerly EverlinQ) EndoAVF System
The WavelinQ endoAVF system is a catheter-based system for the endovascular creation of an arteriovenous fistula (AVF) in patients requiring hemodialysis. The system consists of a pair of over-the-wire catheters with magnets arranged to pull them into alignment and opposition. The venous catheter contains a spring-loaded radiofrequency (RF) electrode, and the arterial cathete…
WavelinQ (formerly EverlinQ) EndoAVF System
The WavelinQ endoAVF system is a catheter-based system for the endovascular creation of an arteriovenous fistula (AVF) in patients requiring hemodialysis. The system consists of a pair of over-the-wire catheters with magnets arranged to pull them into alignment and opposition. The venous catheter contains a spring-loaded radiofrequency (RF) electrode, and the arterial cathete…
Monarch eTNS for Attention-Deficit/Hyperactivity Disorder
The Monarch eTNS is an external trigeminal nerve stimulator for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 7 to 12 years who are not currently taking prescription ADHD medication.
Monarch eTNS for Attention-Deficit/Hyperactivity Disorder
The Monarch eTNS is an external trigeminal nerve stimulator for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 7 to 12 years who are not currently taking prescription ADHD medication.